Recombinant Human Tumor Necrosis Factor-alpha (rHuTNF-alpha)

Produktübersicht

• Artikelname: Recombinant Human Tumor Necrosis Factor-alpha (rHuTNF-alpha)
• Artikelnummer: BWT-PR1125
• Hersteller Artikelnummer: PR1125
• Alternativnummer: BWT-PR1125-10UG,BWT-PR1125-50UG,BWT-PR1125-1.0MG
• Hersteller: Bioworld Technology
• Kategorie: Proteine/Peptide

Produktbeschreibung

Tumor necrosis factor alpha (TNF-alpha), also called cachectin, is produced by neutrophils, activated lymphocytes, macrophages, NK cells, LAK cells, astrocytes endothelial cells, smooth muscle cells and some transformed cells. TNF-alpha occurs as a secreted, soluble form and as a membrane-anchored form, both of which are biologically active. The naturally-occurring form of TNF-alpha is glycosylated, but non-glycosylated recombinant TNF-alpha has comparable biological activity. The biologically active native form of TNF-alpha is reportedly a trimer. Human and murine TNF-alpha show approximately 79% homology at the amino acid level and crossreactivity between the two species. Two types of receptors for TNF-alpha have been described and virtually all cell types studied show the presence of one or both of these receptor types.

Produkteigenschaften

• Molekulargewicht: Approximately 17.5 kDa. The recombinant protein preparation is a mixture of a 158 amino acid residue form containing an N-terminal methionine and a 157 amino acid residue form with the sequence of mature human TNF-alpha.
• Quelle: Escherichia coli.
• Reinheit: >95% by SDS-PAGE and HPLC analyses.
• Formulierung: Sterile Filtered White lyophilized (freeze-dried) powder.
• Sequenz: VRSSSRTPSD KPVAHVVANP QAEGQLQWLN RRANALLANG VELRDNQLVVPSEGLYLIYS QVLFKGQGCP STHVLLTHTI SRIAVSYQTK VNLLSAIKSP CQRETPEGAE AKPWYEPIYL GGVFQLEKGD RLSAEINRPD YLDFAESGQV YFGIIAL
• Formel: Lyophilized from a 0.2mm filtered concentrated solution in PBS, pH 7.0.

Anwendungsbeschreibung

• Anwendungsbeschreibung: We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at <-20C. Further dilutions should be made in appropriate buffered solutions.